Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03060902 · ClinicalTrials.gov registry record · NA
Preschooler Emotion Regulation in the Context of Maternal Borderline Personality Disorder
A NA study of Borderline Personality Disorder and Emotional Problem, sponsored by University of Oregon.
- Completed
- Registry status
- NA
- Development phase
- 93
- Enrollment target
- 1
- Study location
NCT03060902: Completed NA study of Borderline Personality Disorder and Emotional Problem, sponsored by University of Oregon.
NCT03060902 is a NA study of Borderline Personality Disorder and Emotional Problem that has completed, run by University of Oregon. The registered enrollment target is 93 participants, roughly in line with the 102-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03060902, a NA study of Borderline Personality Disorder and Emotional Problem, has completed, sponsored by University of Oregon.
- COMPLETED
- Registry status
- NA
- Development phase
- 93 participants
- Enrollment target
- 1
- Study location
Study Summary
Offspring of mothers with Borderline Personality Disorder (BPD) are at serious risk for developing mental illness at every stage of their life, and yet little is known about how this risk is transmitted. This study will leverage Dialectical Behavior Therapy Skills as an experimental intervention to determine if preschool emotion regulation develops more rapidly as a result of improvements in mothers' ability to regulate her own emotions. The knowledge from this study will identify a modifiable pathway by which maternal BPD places offspring at risk for later mental disorders and will quantify how much improvement in children's ability to regulate their emotions can be achieved by treating mothers alone.
Primary Outcome
Difficulties with Emotion Regulation Scale; Minimum score = 36, Maximum score = 180; higher scores indicate great difficulties with emotion regulation
Conditions Studied
Interventions
- BEHAVIORAL Dialectical Behavior Therapy Skills
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2017-10-23 |
| Est. Completion | 2022-05-04 |
| Phase | NA |
What the finished NCT03060902 record still lists
NCT03060902 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, roughly in line with the 102-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target.
The record links to 2 conditions, with Borderline Personality Disorder appearing as the primary indexed condition, and to 1 intervention - of which Dialectical Behavior Therapy Skills is the first listed.
NCT03060902 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03060902 about?
NCT03060902 is a clinical study titled "Preschooler Emotion Regulation in the Context of Maternal Borderline Personality Disorder". Offspring of mothers with Borderline Personality Disorder (BPD) are at serious risk for developing mental illness at every stage of their life, and yet little is known about how this risk is transmitted. This study will leverage Dialectical Behavior Therapy Skills as an experimental intervention to ...
What is the current status of trial NCT03060902?
This trial is currently completed. It is a NA study. The enrollment target is 93 participants. The study started on 2017-10-23. Estimated completion is 2022-05-04.
What conditions does trial NCT03060902 study?
This clinical trial studies the following conditions: Borderline Personality Disorder, Emotional Problem.
What interventions are being tested in trial NCT03060902?
The interventions under investigation include: Dialectical Behavior Therapy Skills (BEHAVIORAL).
Who is sponsoring clinical trial NCT03060902?
This trial is sponsored by University of Oregon, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03060902 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Borderline Personality Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03060902's enrollment target sits among peer trials
93 7th of 16 higher than 10 of 16 other Borderline Personality Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Borderline Personality Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
RECRUITING · NA
-
Cognitive Reappraisal Training for Borderline Personality (BPD)
RECRUITING · NA
-
Treatment of Borderline Personality Disorder With rTMS
RECRUITING · NA
-
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
RECRUITING · NA
-
PILOT Phase: BPD Study
ACTIVE NOT RECRUITING · NA
-
Neurofeedback for Borderline Personality Disorder
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI